Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer

Annals of Oncology

Volumn 7, Issue 10, 1996, Pages 1065-1070

  Chollet, P ^a   Bensmaine M A ^b   Brienza, S ^c   Deloche, C ^a   Cure H ^a   Caillet, H ^d   Cvitkovic, E ^d  

^a CENTRE JEAN PERRIN   (France)

^b SANOFI   (France)

^c Debiopharm   (France)

^d HÔPITAL PAUL BROUSSE   (France)

Author keywords

advanced ovarian cancer; oxaliplatin; salvage therapy

Indexed keywords

OXALIPLATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEUROTOXICITY; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0030480745     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010500     Document Type: Article

References (33)

1. Sutton GP, Stehman FB, Einhorn LH et al. Ten years follow-up of patients receiving cisplatin, doxoruhicin and cyclophosphamide (PAC) chemotherapy for stage III and IV advanced ovarian carcinima. J Clin Oncol 1989; 7: 223-9.
2. Pater JL, Carmichael JA, Krepart GV et al. Second-line chemotherapy of stage III-IV ovarian carcinoma. A randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease alter doxorubicin and cisplatin. Cancer Treat Rep 1987; 71: 277-81.
3. Ozols RF, Young RC. Ovarian cancer. Chemotherapy of ovarian cancer. Semin Oncol 1991; 18: 222-32.
4. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-93.
5. Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population. J Clin Oncol 1992; 10: 513-4.
6. Gore ME, Friatt I, Wiltshaw E et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990; 36: 207-11.
7. Schink JC, Harris LS, Grosen ER et al. Altretamine (hexalen) an effective salvage chemotherapy after paclitaxel (Taxol) in women with recurrent platinum resistant ovarian cancer. Proc Am Soc Clin Oncol 1995; 14: 275 (Abstr 770).
8. Thigpen JT, Blessing JA, Ball H et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group Study. J Clin Oncol 1994; 12: 1748-53.
9. Kavanagh J, Kudelka A, Freedman R et al. Taxotere (docetaxel): Activity in platinum-refractory ovarian cancer and amelioration of toxicity. Proc Am Soc Clin Oncol 1994; 13: 237 (Abstr 732).
10. Armstrong D, Rowinsky R, Donchower R et al. A phase II trial topotecan as salvage therapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol 1995; 14: 275 (Abstr 769).
11. Burchenal JH, Lokys L, Turkevich J et al. 1,2-Diaminocyclohehane platinum derivatives of potential clinical value. Recent results. Cancer Res 1980; 74: 146-55.
12. Myers TG, Paull KD, Fojo AT et al. Multivariate analysis of high-flux screening data using the DISCOVER computer program package: Integrated analysis of activity patterns and molecular structure features of platinum complexes. Proc Am Assoc Cancer Res 1994; 35: 371.
13. Misset JL, Kidani Y, Gastiaburu J et al. Oxalatoplatinum (L-OHP): Experimental and clinical studies. In Howell SB (ed): Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, 374. New York: Plenum Press 1991.
14. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993; 53: 5970-6.
15. Alvarez M, Ortuzar W, Rixe O et al. Cross resistance patterns of cell lines selected with platinum suggest differences in the activities and mechanisms of resistance of platinum analogues. Proc Am Assoc Cancer Res 1994; 35: 439.
16. Mathé G, Chenu E, Bourut C et al. Experimental study of three platinum complexes: CDDP, CBDCA and L-OHP on L1210 leukemia. Alternate or simultaneous association of two platinum complexes. Proc Am Assoc Cancer Res 1989; 30: 872.
17. Ortuzar W, Paull K, Rixe O et al. Comparison of the activity of cisplatin (CP) and oxaliplatin (OXALI) alone or in combination in parental and drug resistant sublines. Proc Am Assoc Cancer Res 1994; 35: 332.
18. Brienza S, Vignoud J, Itzhaki M. Oxaliplatin (L-OHP): Global safety in 682 patients. Proceedings of the Seventh International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Amsterdam 1995 (Abstr 140).
19. Extra JM, Espie M, Calvo F et al. Phase I study of oxaliplatin in patients with advanced cancer. Chemother Pharmacol 1990; 25: 299-303.
20. Mathé G, Kidani Y, Misset JL et al. Phase I trial of oxalatoplatinum (L-OHP): A new trial design with dose escalation in each patient. Proc AACR 1986; 27: 190 (Abstr A752).
21. Neijt JP, Ten Bokkel Huiniuk WW, Van der Burg MEL et al. Long term survival in ovarian cancer. Eur J Cancer 1991; 27, 1367-72.
22. Markman M. Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-93.
23. Ozols RF, Ostchega Y, Curt G et al. High-dose carboplatin in refractory ovarian patients. J Clin Oncol 1987; 5: 197-201.
24. Ozols RF, Ostchega Y, Myers CE et al. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 1985; 3: 1246-50.
25. Kavanagh JJ, Nicaise C. Carboplatin in refractory epithelial ovarian cancer: Semin Oncol 1989; 16 (Suppl 5): 45-8.
26. Schilder RJ, LaCreta FP, Perez RP et al. Phase I and pharmacokinetics study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res 1994; 54: 709-17.
27. Burchenal JH, Lokys L, Turkevich J et al. 1,2-Diaminocyclohexane platinum derivatives of potential clinical value. Recent results. Cancer Res 1980; 74: 146-55.
28. Weiss G, Green S, Alberts DS et al. Second-line treatment of advanced measurable ovarian cancer with iproplatin: A Southwest Oncology Group study. Eur J Cancer 1991; 27(2): 135-8.
29. Willemse PHB, Gietcrna JA, Mulder NH et al. Zeniplatin in patients with advanced ovarian cancer: A phase II study with a third generation platinum complex. Eur J Cancer 1993; 29A(3): 359-62.
30. Gietema JA, Veldhuis GJ, Guchelaar HJ et al. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Br J Cancer 1995; 71: 1302-7.
31. Kavanagh JJ, Edwards CL, Freedman RS et al. A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer. Gynecologic Oncol 1995; 58: 106-9.
32. Misset JL, Soulié P, Férérrès M et al. High activity of combined oxaliplatin (L-OHP) cisplatin (CP) as salvage treatment in pretreated ovarian cancer (OC). Proc Am Soc Clin Oncol 1994; 13:273 (Abstr 876).
33. Louvet C, Bleiberg H, Gamelin E et al. Oxaliplatin (L-OHP) synergistic clinical activity with 5-fluorouracil (FU) in FU resistant colorectal cancer (CRC) patients (pts) is independant of FU ± folinic acid (FA) schedule. Proc Am Soc Clin Oncol 15:206, 1996 (Abstr 467).